Abstract
β-endorphin concentrations have been evaluated in the hypothalamus, pituitary lobes and plasma after 1-and 3-week treatment with 2-Br-α-ergocriptine or lisuride, two potent dopaminergic drugs. Hypothalamic β-endorphin concentrations were significantly decreased after the administration of the dopaminergic agents for 1 or 3 weeks. Similarly, β-endorphin concentrations decreased in the neurointermediate lobe and plasma. After gel chromatography, it appeared that in the anterior pituitary, β-lipotropin concentrations were unchanged or lightly increased concomitantly with a decrease of β-endorphin. Our data indicate that, both in the hypothalamus and the neurointermediate pituitary lobe, β-endorphin is under an inhibitory dopaminergic tone. The latter may also play a role in inhibiting β-endorphin cleavage from β-lipotropin in the anterior pituitary.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
